Press releases
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
- Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade Marinus Pharmaceuticals Inc (61Y:DEU) traded at 1.11, 6.73% above its 52-week low of 1.04, set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.09 |
---|---|
High | 1.12 |
Low | 1.07 |
Bid | 1.09 |
Offer | 1.14 |
Previous close | 1.15 |
Average volume | 754.00 |
---|---|
Shares outstanding | 54.93m |
Free float | 54.31m |
P/E (TTM) | -- |
Market cap | 66.47m USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 15 minutes, as of Jul 04 2024.
More ▼